Key result
During a 2-year follow-up of patients with tachyarrhythmias receiving antiarrhythmic therapy, 25 patients died, primarily from pump failure or noncardiac causes, with no cardiac deaths in the paroxysmal atrial fibrillation group.
Observational (n=455)
Yes
In a Japanese cohort, long-term antiarrhythmic therapy showed a shift away from slow kinetic Na channel blockers for ventricular tachycardia, aligning with post-CAST evidence, while transition to chronic AF was notably absent in patients on calcium antagonists.
Answers are grounded in this paper and cite their sources.
May support antiarrhythmic safety in tachyarrhythmias; hypothesis-generating and leaves open need for randomized confirmation.
Based on the results of the Cardiac Arrhythmia Suppression Trial (CAST), strategies for the treatment of tachyarrhythmias have changed rapidly. The Japanese Antiarrhythmics Long-Term (JALT) study was planned to investigate the present methods for choosing antiarrhythmic drugs, and the effects on long-term prognosis in patients with tachyarrhythmias in Japan. Following a 6-month preliminary study (JALT-1), there was a multicenter nonrandomized prospective study (JALT-2), with a 2-year follow-up, of patients with paroxysmal atrial fibrillation (PAF), sustained ventricular tachycardia (SVT) and nonsustained VT (NSVT). Four hundred fifty-five patients were registered, and 361 of them (79%) were analyzed. Cerebral infarction occurred in 10 of 193 patients (5.2%) with PAF. Transition to chronic AF was observed in 21 patients (10.9%), but in none of the patients receiving Ca antagonist therapy. Twenty-five patients died: 5 deaths were arrhythmic, 10 were because of pump failure, and 9 were noncardiac. The most significant difference in drug selection between JALT-1 and JALT-2 was the increase in the use of slow kinetic Na channel blockers for PAF and the decrease in the use of the same agents for VT in the JALT-2 study. A marked change of therapeutic strategy occurred in JALT-2 compared with JALT-1. Most patients with a poor prognosis had underlying heart diseases and heart failure, but the per annum rate of death by arrhythmia and pump failure in JALT-2 was less than that in JALT-1.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (2001) conducted an observational in Tachyarrhythmias (paroxysmal atrial fibrillation, sustained ventricular tachycardia, nonsustained ventricular tachycardia) (n=455). Antiarrhythmic drug therapy was evaluated on 2-year prognosis (death, complications, and transition to chronic atrial fibrillation). During a 2-year follow-up of patients with tachyarrhythmias receiving antiarrhythmic therapy, 25 patients died, primarily from pump failure or noncardiac causes, with no cardiac deaths in the paroxysmal atrial fibrillation group.
Synapse has enriched 10 related papers. Consider them for comparative context: